vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Forestar Group Inc.（FOR）财务数据对比。点击上方公司名可切换其他公司
Forestar Group Inc.的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.8倍（$273.0M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 5.6%，领先28.9%），Forestar Group Inc.同比增速更快（9.0% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $-157.1M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs -9.6%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
福雷斯特集团是一家住宅地块开发企业，总部位于得克萨斯州阿灵顿，业务覆盖美国21个州的51个市场。截至2020年12月31日的12个月内，该公司交付了11518块住宅地块，目前在纽约证券交易所上市，自2002年起就是美国规模最大的住宅建筑商D.R. Horton的控股子公司。
CPRX vs FOR — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $273.0M |
| 净利润 | $52.7M | $15.4M |
| 毛利率 | 82.9% | 20.1% |
| 营业利润率 | 40.5% | 7.6% |
| 净利率 | 34.5% | 5.6% |
| 营收同比 | 7.6% | 9.0% |
| 净利润同比 | -5.8% | -6.7% |
| 每股收益（稀释后） | $0.40 | $0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $273.0M | ||
| Q3 25 | $148.4M | $670.5M | ||
| Q2 25 | $146.6M | $390.5M | ||
| Q1 25 | $141.4M | $351.0M | ||
| Q4 24 | $141.8M | $250.4M | ||
| Q3 24 | $128.7M | $551.3M | ||
| Q2 24 | $122.7M | $318.4M | ||
| Q1 24 | $98.5M | $333.8M |
| Q4 25 | $52.7M | $15.4M | ||
| Q3 25 | $52.8M | $86.9M | ||
| Q2 25 | $52.1M | $32.9M | ||
| Q1 25 | $56.7M | $31.6M | ||
| Q4 24 | $55.9M | $16.5M | ||
| Q3 24 | $43.9M | $81.5M | ||
| Q2 24 | $40.8M | $38.7M | ||
| Q1 24 | $23.3M | $45.0M |
| Q4 25 | 82.9% | 20.1% | ||
| Q3 25 | 84.7% | 22.3% | ||
| Q2 25 | 85.9% | 20.4% | ||
| Q1 25 | 87.3% | 22.6% | ||
| Q4 24 | 84.7% | 22.0% | ||
| Q3 24 | 85.0% | 23.9% | ||
| Q2 24 | 87.4% | 22.5% | ||
| Q1 24 | 87.3% | 24.9% |
| Q4 25 | 40.5% | 7.6% | ||
| Q3 25 | 44.7% | 16.9% | ||
| Q2 25 | 45.2% | 11.2% | ||
| Q1 25 | 44.8% | 11.6% | ||
| Q4 24 | 44.3% | 8.7% | ||
| Q3 24 | 39.6% | 19.7% | ||
| Q2 24 | 44.2% | 16.2% | ||
| Q1 24 | 27.5% | 17.6% |
| Q4 25 | 34.5% | 5.6% | ||
| Q3 25 | 35.6% | 13.0% | ||
| Q2 25 | 35.6% | 8.4% | ||
| Q1 25 | 40.1% | 9.0% | ||
| Q4 24 | 39.4% | 6.6% | ||
| Q3 24 | 34.1% | 14.8% | ||
| Q2 24 | 33.2% | 12.2% | ||
| Q1 24 | 23.6% | 13.5% |
| Q4 25 | $0.40 | $0.30 | ||
| Q3 25 | $0.42 | $1.70 | ||
| Q2 25 | $0.41 | $0.65 | ||
| Q1 25 | $0.45 | $0.62 | ||
| Q4 24 | $0.44 | $0.32 | ||
| Q3 24 | $0.35 | $1.59 | ||
| Q2 24 | $0.33 | $0.76 | ||
| Q1 24 | $0.19 | $0.89 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $211.7M |
| 总债务越低越好 | — | $793.2M |
| 股东权益账面价值 | $954.3M | $1.8B |
| 总资产 | $1.1B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.44× |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $211.7M | ||
| Q3 25 | $689.9M | $379.2M | ||
| Q2 25 | $652.8M | $189.2M | ||
| Q1 25 | $580.7M | $174.3M | ||
| Q4 24 | $517.6M | $132.0M | ||
| Q3 24 | $442.3M | $481.2M | ||
| Q2 24 | $375.7M | $359.2M | ||
| Q1 24 | $310.4M | $416.2M |
| Q4 25 | — | $793.2M | ||
| Q3 25 | — | $802.7M | ||
| Q2 25 | — | $872.8M | ||
| Q1 25 | — | $872.5M | ||
| Q4 24 | — | $806.8M | ||
| Q3 24 | — | $706.4M | ||
| Q2 24 | — | $706.1M | ||
| Q1 24 | — | $705.7M |
| Q4 25 | $954.3M | $1.8B | ||
| Q3 25 | $920.2M | $1.8B | ||
| Q2 25 | $856.0M | $1.7B | ||
| Q1 25 | $794.3M | $1.6B | ||
| Q4 24 | $727.6M | $1.6B | ||
| Q3 24 | $660.9M | $1.6B | ||
| Q2 24 | $608.7M | $1.5B | ||
| Q1 24 | $561.4M | $1.5B |
| Q4 25 | $1.1B | $3.2B | ||
| Q3 25 | $1.1B | $3.1B | ||
| Q2 25 | $971.9M | $3.1B | ||
| Q1 25 | $908.9M | $3.0B | ||
| Q4 24 | $851.4M | $3.0B | ||
| Q3 24 | $772.0M | $2.8B | ||
| Q2 24 | $706.4M | $2.7B | ||
| Q1 24 | $646.7M | $2.6B |
| Q4 25 | — | 0.44× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.47× | ||
| Q1 24 | — | 0.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $-157.0M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $-157.1M |
| 自由现金流率自由现金流/营收 | 29.4% | -57.5% |
| 资本支出强度资本支出/营收 | 0.0% | 0.0% |
| 现金转化率经营现金流/净利润 | 0.85× | -10.19× |
| 过去12个月自由现金流最近4个季度 | — | $93.0M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $-157.0M | ||
| Q3 25 | $32.4M | $256.3M | ||
| Q2 25 | $71.3M | $15.8M | ||
| Q1 25 | $60.0M | $-19.8M | ||
| Q4 24 | $70.9M | $-450.0M | ||
| Q3 24 | $72.9M | $119.2M | ||
| Q2 24 | $64.1M | $-61.7M | ||
| Q1 24 | $31.9M | $-59.2M |
| Q4 25 | $44.9M | $-157.1M | ||
| Q3 25 | — | $255.6M | ||
| Q2 25 | $71.3M | $15.0M | ||
| Q1 25 | — | $-20.5M | ||
| Q4 24 | $70.8M | — | ||
| Q3 24 | $72.6M | $118.4M | ||
| Q2 24 | $64.1M | $-62.3M | ||
| Q1 24 | $31.7M | $-59.8M |
| Q4 25 | 29.4% | -57.5% | ||
| Q3 25 | — | 38.1% | ||
| Q2 25 | 48.6% | 3.8% | ||
| Q1 25 | — | -5.8% | ||
| Q4 24 | 49.9% | — | ||
| Q3 24 | 56.4% | 21.5% | ||
| Q2 24 | 52.3% | -19.6% | ||
| Q1 24 | 32.2% | -17.9% |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | 0.1% | 0.0% | ||
| Q3 24 | 0.2% | 0.1% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.2% | 0.2% |
| Q4 25 | 0.85× | -10.19× | ||
| Q3 25 | 0.61× | 2.95× | ||
| Q2 25 | 1.37× | 0.48× | ||
| Q1 25 | 1.06× | -0.63× | ||
| Q4 24 | 1.27× | -27.27× | ||
| Q3 24 | 1.66× | 1.46× | ||
| Q2 24 | 1.57× | -1.59× | ||
| Q1 24 | 1.37× | -1.32× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
